{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-078102","form_type":"8-K","ticker":"CLRB","cik":"0001279704","company_name":"Cellectar Biosciences, Inc.","filed_at":"2025-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.571775+00:00","generated_at":"2026-05-17T12:52:22.382684+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Cellectar to pursue accelerated NDA for iopofosine I 131 in WM; Q2 net loss $5.4M","bullets":["Plans NDA submission for accelerated approval of iopofosine I 131 in WM, subject to sufficient funding and confirmatory trial initiation.","FDA granted Breakthrough Therapy Designation for iopofosine I 131; EMA decision on conditional approval expected late Q3/early Q4 2025.","Raised ~$9.5M in June/July financings; cash $11.0M at June 30, 2025, plus July net proceeds funds operations into Q2 2026.","CLR 125 Phase 1 TNBC trial protocol submitted to FDA; plan to advance into clinic 4Q 2025/early 2026.","Q2 2025 net loss $5.4M ($3.39 per share); R&D $2.4M, G&A $3.6M; both down YoY."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-078102","json":"https://secwatch.observer/filing/0001104659-25-078102.json","markdown":"https://secwatch.observer/filing/0001104659-25-078102.md","text":"https://secwatch.observer/filing/0001104659-25-078102.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1279704/000110465925078102/0001104659-25-078102-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1279704/000110465925078102/tm2523504d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T12:52:22.382684+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}